Positive Data For Amgen/UCB's Romosozumab In Men With Osteoporosis

Amgen and UCB have demonstrated the efficacy of their osteoporosis treatment romosozumab in men in the Phase III BRIDGE study. This follows Phase III FRAME data in women which will form the basis of a US filing later this year.